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Background: Bipolar disorder is characterized by debilitating episodes of depression and mood 
elevation (mania or hypomania). For most patients, depressive symptoms are more pervasive than 
mood elevation or mixed symptoms, and thus have been reported in individual studies to impose 
a greater burden on affected individuals, caregivers, and society. This article reviews and compiles 
the literature on the prevalence and burden of syndromal as well as subsyndromal presentations of 
depression in bipolar disorder patients.
Methods: The PubMed database was searched for English-language articles using the search terms 
“bipolar disorder,” “bipolar depression,” “burden,” “caregiver burden,” “cost,” “costs,” “economic,” 
“epidemiology,” “prevalence,” “quality of life,” and “suicide.” Search results were manually reviewed, 
and relevant studies were selected for inclusion as appropriate. Additional references were obtained 
manually from reviewing the reference lists of selected articles found by computerized search.
Results: In aggregate, the findings support the predominance of depressive symptoms compared with 
mood elevation/mixed symptoms in the course of bipolar illness, and thus an overall greater burden in 
terms of economic costs, functioning, caregiver burden, and suicide.
Limitations: This review, although comprehensive, provides a study-wise aggregate (rather than a 
patient-wise meta-analytic) summary of the relevant literature on this topic.
Conclusions: In light of its pervasiveness and prevalence, more effective and aggressive treatments for 
bipolar depression are warranted to mitigate its profound impact upon individuals and society. Such 
studies could benefit by including metrics not only for mood outcomes, but also for illness burden.
© 2014 Elsevier B.V. All rights reserved.
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1. Introduction
Bipolar disorder (BD) is a serious, commonly disabling 
psychiatric condition that is tragically, on occasion, fatal. It is 
characterized by recurrent episodes of depression and mood 
elevation (mania or hypomania). Bipolar spectrum illness 
(comprising BD in its broadest sense), including bipolar I 
disorder (BDI, requiring a lifetime history of at least one manic 
episode), bipolar II disorder (BDII, requiring a lifetime history of 
major depressive and hypomanic episodes, without any history 
of mania), and BD not otherwise specified (BDNOS, including 
subthreshold bipolar presentations), may affect as much as 
4.4% of the US population (Merikangas et al., 2007). Despite its 
lower prevalence compared with some other mental disorders, 
such as unipolar major depressive disorder (MDD, which has an 
approximately 3-fold higher lifetime prevalence) and anxiety 
disorders (which in aggregate have an approximately 6-fold 
higher lifetime prevalence) (Kessler et al., 2005), BD causes more 
marked functional impairment (Shippee et al., 2011; Solé et al., 
2012) and greater reduction in quality of life (QOL) (Gutierrez-
Rojas et al., 2008; Sierra et al., 2005). As a result, BD imposes a 
greater economic burden to society (i.e., higher costs) than other 
mental disorders (Kleinman et al., 2005; Peele et al., 2003) and 
constitutes the 12th leading cause of disability worldwide across 
all age groups (World Health Organization, 2008).
The course of bipolar illness is characterized by the 
predominance of depressive symptoms, which are more pervasive 
than mood elevation or mixed symptoms. Prospective studies 
consistently show that BD patients spend more time with 
depressive symptoms than with mood elevation/mixed symptoms 
(Judd et al., 2003; Judd et al., 2002; Kupka et al., 2007). Consequently, 
depressive symptoms compared with mood elevation/mixed 
symptoms have been consistently associated with greater (or at 
least equal) impairments of social and occupational functioning 
(Bonnin et al., 2010; Calabrese et al., 2004; Gitlin et al., 2011) and 
QOL (Gutierrez-Rojas et al., 2008; Revicki et al., 2005; Zhang et al., 
2006). The present article aims to review the prevalence of bipolar 
depression and discuss the impact of depressive symptoms on the 
overall burden of BD.
2. Methods
The PubMed database was searched in February 2013 for 
English-language articles using the following search terms: 
“bipolar disorder,” “bipolar depression,” “burden,” “caregiver 
burden,” “cost,” “costs,” “economic,” “epidemiology,” “preva-
lence,” “quality of life,” and “suicide.” The search results were 
reviewed, and studies related to the epidemiology and burden of 
BD and bipolar depression were manually selected for inclusion 
as appropriate. Additional references were obtained manually 
by reviewing the reference lists of relevant articles found by 
computerized search.
3. Prevalence and epidemiology of bipolar disorder
BD affected an estimated 29.5 million individuals worldwide 
in 2004, according to the World Health Organization (World 
Health Organization, 2008). A more recent (2011) study involving 
a combined sample of 61,392 community-dwelling individuals in 
11 countries, mainly in the Americas, Europe, and Asia, found an 
aggregate lifetime BD prevalence of 2.4% (0.6% BDI, 0.4% BDII, and 
1.4% subthreshold BD) (Merikangas et al., 2011). Of the 11 countries 
examined in this study, the United States had the highest lifetime 
prevalence of bipolar spectrum illness (combined BDI, BDII, and 
subthreshold BD) at 4.4%, while India had the lowest prevalence of 
bipolar spectrum illness at 0.1% (Merikangas et al., 2011).
In the United States, the estimated 12-month prevalence 
rates of BDI, BDII, and subthreshold BD were 0.6%, 0.8%, and 1.4%, 
respectively (Merikangas et al., 2007). BD prevalence decreased 
with increasing age and education level and was higher in 
unemployed/disabled individuals compared with employed 
individuals, but did not appear to be consistently related to gender, 
race/ethnicity, or income (Merikangas et al., 2007). Typical age at 
onset of BD was late adolescence to young adulthood (Merikangas 
et al., 2007). Childhood-onset BD occurs with prevalence estimates 
of 0.1% to 2.5% in pediatric samples, and there is some potentially 
substantive geographic variation (Merikangas et al., 2012; 
Stringaris et al., 2010). For example, childhood-onset BD may be 
more common in the United States than in Europe (Post et al., 
2008). Indeed, among the first 1000 participants in the US-based 
Systematic Treatment Enhancement Program for Bipolar Disorder 
(STEP-BD), 27.7% had childhood onset (age <13 years), which was 
associated with greater number of lifetime depressive and manic 
episodes, and greater likelihood of past suicide attempt, compared 
with adolescent onset (age 13–18 years) and adult onset (age 
>18 years) (Perlis et al., 2004). Thus, childhood-onset BD, which 
may entail greater genetic vulnerability (offspring of parents with 
BD may be at particular risk for this form of BD) (Goodwin and 
Jamison, 2007), could represent one of the more costly forms of BD.
BD has been consistently associated with significant medical 
and psychiatric comorbidity. For example, in the National 
Comorbidity Survey Replication (NCS-R), 94.6% of patients 
with BD reported having at least one comorbid disorder, with a 
mean of 4.6 medical and/or psychiatric comorbidities reported 
by such individuals (Gadermann et al., 2012). Moreover, in a 
Stanley Foundation Bipolar Treatment Outcome Network (SFBN) 
study, among 288 BD patients assessed by structured diagnostic 
interview, 65% had at least one comorbid Axis I disorder, with 
anxiety and substance use disorders being the predominant 
comorbidities (McElroy et al., 2001). In STEP-BD, 58.8% of BD 
patients had at least one medical comorbidity, and the prevalence 
was significantly higher in those with lifetime anxiety and 
substance use disorders (Magalhaes et al., 2012). In addition, 
analysis of the National Hospital Discharge Survey showed that 
among patients discharged with a primary diagnosis of BD, 
74.6% had at least one comorbid condition, and patients with a 
primary diagnosis of BD had a greater burden of most psychiatric 
and some general medical comorbidities, compared with those 
without a BD diagnosis (Weber et al., 2011).
With regard to medical comorbidities, cardiovascular and 
metabolic diseases are particularly prevalent among BD patients, 
who have shown elevated rates of hypertension, obesity, metabolic 
syndrome, and diabetes (Fiedorowicz et al., 2008; Goldstein et 
al., 2011; McIntyre et al., 2005; Vancampfort et al., 2013). A large 
population-based cohort study in Sweden found that patients 
with BD had increased mortality rates due to cardiovascular 
and other medical illnesses, dying of cardiovascular disease, on 
average, 10 years earlier than the general population (Westman et 
al., 2013); these results are consistent with findings from a recent 
review of the literature (Roshanaei-Moghaddam and Katon, 2009). 
Medical illness burden may have important implications for BD 
mood outcomes. For example, in post hoc analyses of two clinical 
trials involving 225 rapid-cycling BDI and BDII participants, 
endocrine/metabolic illness burden was inversely correlated 
with remission from depression, and higher body mass index was 
associated with lower likelihood of response or remission (Kemp 
et al., 2010). Moreover, results from a Canadian population-based 
study associated chronic medical conditions with more severe 
bipolar illness course, poorer functioning, and increased medical 
service utilization among BD patients (McIntyre et al., 2006).
As noted above, psychiatric comorbidities are also particularly 
prevalent in BD patients; more than 90% of BDI and BDII patients 
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in the NCS-R reported at least one comorbid psychiatric condition 
(Merikangas et al., 2007). Anxiety, impulse control, and substance 
use disorders were two to three times more prevalent among 
BD patients than in the general population (Kessler et al., 2005; 
Merikangas et al., 2007). Anxiety disorder comorbidity was 
associated with multiple unfavorable BD illness characteristics, 
including earlier age at first depressive episode and greater 
number of depressive episodes, in a sample of 1416 BD patients, 
and was associated with fewer days well, longer time to recovery 
from depression, shorter time to mood episode relapse, and 
poorer role functioning and QOL, during 12-month prospective 
follow-up of the first 1000 STEP-BD patients (Goes et al., 2012; 
Otto et al., 2006). Similarly, current or past substance use disorder 
was associated with poorer role functioning, lower self-reported 
QOL, and greater likelihood of past suicide attempt among the 
first 1000 STEP-BD participants (Weiss et al., 2005). Among 288 
patients evaluated within the SFBN, current Axis I comorbidity 
was associated with earlier age at BD onset, history of cycle 
acceleration, and development of more severe mood episodes over 
time (McElroy et al., 2001). Patterns of Axis I comorbidity among 
BD patients may be influenced by age. One study demonstrated 
that younger (≤30 years old) BD patients had more comorbidities 
and were more likely to have substance use disorder and anorexia 
compared with older (>30 years old) BD patients, although the 
latter group more frequently had obsessive compulsive disorder 
(Dell’osso et al., 2011).
4. Predominance of depression in bipolar illness course
Individuals with BD have consistently been shown to spend a 
greater proportion of time with depressive symptoms than with 
mood elevation/mixed symptoms. Among US-based participants 
in the National Institute of Mental Health (NIMH) Collaborative 
Depression Study, 146 BDI and 86 BDII patients were followed 
prospectively with weekly symptom status ratings, assessed by 
interviews by trained raters every 6 months for the first 5 years, 
then yearly, for a mean of 12.8 and 13.4 years, respectively (Judd 
et al., 2003; Judd et al., 2002). On average, BDI patients spent 
31.9% of weeks with depressive symptoms (22.9% subsyndromal 
and 8.9% syndromal), compared with 9.3% of weeks with mood 
elevation (2.4% subsyndromal, 4.6% syndromal hypomanic, 
and 2.3% syndromal manic), 5.9% of weeks with cycling/mixed 
symptoms, and 52.7% of weeks with euthymia (Judd et al., 2002). 
BDII patients, compared with BDI patients, spent a numerically 
greater proportion of time depressed: 50.3% of total weeks with 
depressive symptoms (37.4% subsyndromal and 12.9% syndromal), 
1.3% of weeks with hypomania (0.4% subsyndromal and 0.9% 
syndromal), 2.3% of weeks with cycling/mixed symptoms, and 
46.1% of weeks with euthymia (Judd et al., 2003).
As depicted in Figure 1, other prospective studies have 
consistently yielded similar results despite variable geography 
and methodology, showing that BD patients have more frequent 
depressive symptoms than mood elevation/mixed symptoms (in 
aggregate, 34.1% of the time depressed versus 12.3% of the time 
elevated/mixed) (De Dios et al., 2010; Joffe et al., 2004; Judd 
et al., 2003; Judd et al., 2002; Kupka et al., 2007). For example, 
among 405 US and European SFBN patients with BDI evaluated 
for 1 year with prospective daily self-ratings using the NIMH Life 
Chart Methodology, results showed subsyndromal/syndromal 
depression 36.0% of the time, hypomania 11.5%, mania 1.0%, 
cycling 3.7%, and euthymia 47.7% of the time (Kupka et al., 2007). 
In this same study, 102 BDII patients had subsyndromal/syndromal 
depression 36.9% of the time, hypomania 9.8%, subsyndromal 
hypomania 0.2%, cycling 2.8%, and euthymia 50.2% of the time 
(Kupka et al., 2007). In a different Canadian study of 138 BDI and 
BDII patients followed prospectively for at least one year (mean 
1227 days) with mood ratings recorded by clinicians at each visit 
using a modified version of the NIMH Life Chart Methodology, 
40.9% of the time was spent with subsyndromal/syndromal 
depression, compared with 6% with subsyndromal/syndromal 
mood elevation (Joffe et al., 2004). In a prospective 18-month 
follow-up of a Spanish cohort of 296 BD spectrum patients (BDI, 
BDII, BDNOS, cyclothymia, and schizoaffective disorder-bipolar 
type), quarterly assessments were made, including estimation 
of days spent in mood episodes and days spent euthymic since 
the last visit (De Dios et al., 2010). This study yielded broadly 
consistent results regarding the primacy of depressive compared 
with mood elevation symptoms; patients spent 23.7% of days 
depressed, 8.3% of days elevated, 2.6% of days mixed, and 65.5% of 
days euthymic (De Dios et al., 2010).
Effects of gender and age on the prevalence of bipolar 
depression have also been studied. In an SFBN study involving 
406 female and 305 male BDI and BDII patients followed for up 
to 7 years, the predominance of depressive symptoms appeared 
more pronounced in women (Altshuler et al., 2010). Thus, women 
were depressed for 35.6% of the time compared with 28.7% for 
men, whereas men spent a greater proportion of time euthymic 
(56.9% for men versus 50.4% for women) (Altshuler et al., 2010). In 
contrast, men and women had similar percentages of time elevated 
(14.1% for women versus 14.4% for men) (Altshuler et al., 2010). In 
a separate study involving 164 STEP-BD patients seen on average 
once per month, 47 women of menopausal transition age (45–
55 years) and 30 similar-aged men, plus 48 women and 39 men 
aged 30–40 years, were monitored naturalistically for a mean of 
30 months (Marsh et al., 2009). Among these patients, women 
at the menopausal transition age spent a greater proportion of 
visits with depressive symptoms and a lower proportion of visits 
euthymic compared with the pooled comparison group of men 
and younger premenopausal women (Marsh et al., 2009).
5. Socioeconomic burden of bipolar disorder
BD imposes substantial economic and psychosocial burdens on 
individuals as well as society. Regarding economic burden in the 
United States, indirect costs (e.g., lost productivity of patients and 
caregivers) may be approximately 4-fold higher than direct costs 
(e.g., treatment-related costs of inpatient and outpatient care, and 
treatment-unrelated costs of services used by BD patients, such as 
Fig. 1. Percentage of time spent depressed or elevated/cycling/mixed in bipolar 
disorder (BD): summary of findings from prospective studies (De Dios et al., 2010; 
Joffe et al., 2004; Judd et al., 2003; Judd et al., 2002; Kupka et al., 2007). Data from 
* Judd et al. 2002 (bipolar I disorder [BDI]); † Judd et al. 2003 (bipolar II disorder 
[BDII]); ‡ Kupka et al. 2007 (BDI); § Kupka et al. 2007 (BDII); || Joffe et al. 2004 
(BDI/II); and ¶ De Dios et al. 2010 (BD spectrum); # Pooled average across studies, 
weighted based on sample size.
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the criminal justice system). Thus, in 2009, the estimated total cost 
of BDI and BDII in the United States was $151 billion, consisting of 
$30.7 billion in direct and $120.3 billion in indirect costs (Figure 2) 
(Dilsaver, 2011; Wyatt and Henter, 1995). These data were derived 
from a 1991 estimate, adjusted for the increased prevalence of 
bipolar disorders in 2009, inflation, and population growth, and 
demonstrate the primacy of indirect compared with direct costs 
(Dilsaver, 2011; Wyatt and Henter, 1995). Analysis of employer-
sponsored health insurance claims for 1.7 million individuals in 
1996 showed that BD was the most expensive behavioral health 
diagnosis, resulting in higher annual health care costs for both 
individual patients and insurance plans (Peele et al., 2003). A more 
recent analysis of employer-based health plan data for 80,000 
enrollees from 2004 to 2007 found the monthly per-patient costs 
of BD to be greater than those of all other psychiatric or medical 
diagnoses, with the exception of diabetes concomitant with 
coronary artery disease (Williams et al., 2011). In these and other 
analyses of health plan data, inpatient treatment (psychiatric and/
or non-psychiatric) accounted for the greatest proportion of direct 
health care costs associated with BD, outweighing the costs of 
medications and outpatient visits (Bryant-Comstock et al., 2002; 
Guo et al., 2008; Guo et al., 2007; Peele et al., 2003; Williams et 
al., 2011).
In addition to the direct economic costs of health care, BD 
appears to be associated with even greater indirect costs due 
to unemployment and lost workplace productivity. In a study 
of 219 patients with BDI compared with 198 patients without 
serious mental illness, recruited from physician practices across 
the United States, BDI patients were significantly more likely to 
have been fired or laid off, or to have received short- or long-term 
disability for a medical reason (McMorris et al., 2010). Similarly, 
patients with BD (or subthreshold presentations of BD) in the 
NIMH Epidemiological Catchment Area Program database were 
approximately twice as likely as individuals without a mental 
disorder to have relied upon welfare or disability benefits (Judd 
and Akiskal, 2003). In addition, BD patients have high rates of 
absenteeism, even in comparison with unipolar MDD patients, 
which imposes a significant economic burden on employers 
(Gardner et al., 2006; Kessler et al., 2006; McMorris et al., 2010; 
Shippee et al., 2011; Zimmerman et al., 2010). In an NCS-R–derived 
nationally representative sample of 3378 US workers, BD was 
associated with 65.5 lost workdays per worker per year, yielding a 
projected annual salary-equivalent cost of lost productivity in the 
United States of $14 billion (Kessler et al., 2006). It is important 
to note that this study included assessment of absenteeism 
(missed days of work) as well as presenteeism (low performance 
while at work) in the estimation of lost workdays (Kessler et al., 
2006). BD results in lost productivity not only for patients, but 
also for their family members, whose workforce participation is 
compromised by caregiver responsibilities. In 1991, lost family 
member occupational productivity was estimated to account for 
16.5% of the indirect costs, or 13.8% of the total costs, of BD in the 
United States (Wyatt and Henter, 1995).
6. Impact of bipolar depression on the socioeconomic burden 
of bipolar disorder
Depressive symptoms contribute substantially to the 
socioeconomic burden of BD and may account for a greater 
proportion of the overall costs of BD compared with manic or 
mixed symptomatology. This could be due to much higher indirect 
costs for depression (which is far more pervasive over time than 
mood elevation) due to lost productivity, even though the direct 
costs of manic/mixed symptoms exceed those of depression 
because of higher inpatient treatment expenses (Bryant-Comstock 
et al., 2002). In the nationally representative sample of 3378 US 
Fig. 2. Estimated indirect and direct costs of bipolar disorder in the United States in 2009 (in billions) (Dilsaver, 2011; Wyatt and Henter, 1995). *Criminal justice system use, 
suicide, or suicide attempt. Data from Dilsaver, S.C., 2011, J Affect. Disord. 129 (1-3), 79–83; Wyatt, R.J., Henter, I., 1995, Soc. Psychiatry Psychiatr Epidemiol. 30 (5), 213–219.
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workers from the NCS-R (described above), BD patients with at 
least one prior-year major depressive episode had greater levels 
of absenteeism, presenteeism, and total lost workdays compared 
with BD patients with only manic/hypomanic episode(s) during 
the previous 12 months (Kessler et al., 2006). In a sample of 
412 BD outpatients (age <65 years) followed longitudinally over 
24 months, unemployed compared with employed individuals 
had significantly greater severity of depressive but not manic/
hypomanic symptoms (Simon et al., 2008). During monitoring, 
those having at least one major depressive episode were 15% 
less likely to be employed, and if employed, missed an additional 
4 workdays per month, compared with those without significant 
depressive symptoms (Simon et al., 2008). In contrast, patients 
with at least one manic or hypomanic episode did not differ 
significantly from those without significant manic/hypomanic 
symptoms in terms of employment rates or number of missed 
workdays (Simon et al., 2008). Similarly, in a systematic review 
including nine prospective studies (N=3184), bipolar depression 
predicted worse employment status and/or occupational 
functioning more consistently than did mood elevation symptoms 
(Gilbert and Marwaha, 2012).
7. Impact of bipolar depression on individual functioning 
and quality of life
Beyond its impact on work functioning, bipolar depression 
is associated with substantial impairment of other domains of 
individual functioning, as well as reduced QOL. In a prospective 
follow-up study of 336 BDI and 105 BDII patients, depression 
symptom severity, independent of co-occurring manic/
hypomanic symptoms, was consistently and strongly associated 
with functional impairment across multiple domains (work, 
social, household, and other activities) (Simon et al., 2007). On 
the other hand, manic/hypomanic symptom severity was less 
robustly associated with functional impairment in these domains, 
and the effect was further diminished after adjusting for co-
occurring depressive symptoms (Simon et al., 2007). Similarly, 
among 158 BDI and 133 BDII patients followed prospectively 
for a mean of 15 years in the NIMH Collaborative Depression 
Study, depressive symptom severity correlated positively with 
psychosocial disability, to a similar or greater degree than manic/
hypomanic symptom severity (Judd et al., 2005).
Cross-sectional and retrospective assessments have yielded 
similar findings as the prospective studies described above. Thus, 
in the NCS-R, 87.4% of BD patients reported severe role impairment 
due to a major depressive episode in the preceding 12 months, 
whereas only 56.6% reported such a level of role impairment due to 
a prior-year manic/hypomanic episode (Merikangas et al., 2007). 
In another study of 32 currently depressed patients compared 
with 31 currently manic/hypomanic BD patients, the depressed 
patients reported significantly greater impairments in autonomy, 
cognitive functioning, interpersonal relationships, leisure time, 
and overall functioning (Rosa et al., 2010). In yet another study of 
46 BDI patients, prior-year syndromal depression, but not prior-
year syndromal mania/hypomania, was associated with poorer 
global, social, and work functioning (Goldberg and Harrow, 2011).
Several studies have associated not only syndromal, but also 
subsyndromal, depression with functional impairment in BD 
patients, and evidence suggests a dose-response relationship 
between depression severity and degree of functional impairment 
(Figure 3) (Altshuler et al., 2006; Bonnin et al., 2010; Goldberg and 
Harrow, 2011; Judd et al., 2005; Marangell et al., 2009; Solé et al., 
2012). Subsyndromal manic/hypomanic symptoms, in contrast, 
have not consistently predicted poorer functional outcomes 
(Bonnin et al., 2010; Goldberg and Harrow, 2011; Judd et al., 2005). 
Moreover, in a study involving longitudinal follow-up of 85 BDI 
patients who achieved symptomatic recovery following a recent 
manic or hypomanic episode, residual depressive (but not manic/
hypomanic) symptoms were associated with persistent functional 
impairment following symptomatic recovery, and longer delay 
from symptomatic to functional recovery (Gitlin et al., 2011).
Cognitive impairment, a consistent finding in studies of 
euthymic BD patients compared with healthy individuals, may 
be even more pronounced in the setting of depressive symptoms 
(Bourne et al., 2013; Kurtz and Gerraty, 2009). Thus, among 
32 euthymic BDI and BDII patients, subthreshold depression 
(but not mood elevation) at baseline was the only significant 
predictor of worse cognitive functioning at 4-year follow-up 
(Bonnin et al., 2010). Likewise, in a meta-analysis of 31 studies 
involving 1276 euthymic BD patients, residual depressive (but 
not manic) symptoms were related to poorer performance on 
measures of memory, processing speed, and executive function 
(Bourne et al., 2013). However, the number of prior manic (but not 
prior depressive) episodes was associated with poorer cognitive 
performance on measures of verbal memory and processing 
speed (Bourne et al., 2013). Indeed, in a different meta-analysis 
of 60 studies assessing neurocognitive deficits in BD patients in 
different mood states (42 studies in euthymic, 13 in manic, and 
5 in depressed patients), deficits in not only depressed but also 
manic patients were more pronounced than in euthymic patients, 
especially in verbal learning (Kurtz and Gerraty, 2009).
Quality of life, a measure reflecting subjective well-being 
across multiple life domains, has been consistently lower in BD 
patients than in the general population, and may even be lower 
than in unipolar MDD patients (Depp et al., 2006; Gutierrez-
Rojas et al., 2008; Miller et al., 2013; Sierra et al., 2005; Yatham 
et al., 2004). Among 920 recently depressed BD patients, greater 
depression symptom severity was associated with reduced 
QOL across multiple domains (Yatham et al., 2004). Similarly, 
among the first 2000 participants in STEP-BD, those who were 
depressed at study entry had lower self-reported mental and 
overall QOL, compared not only with those who were manic/
hypomanic, but also with those who were euthymic (Zhang et 
al., 2006). Similarly, other studies have confirmed the association 
of depression with reduced QOL in BD patients, whereas mania/
hypomania is less consistently associated with lower QOL (Amini 
and Sharifi, 2012; Depp et al., 2006; Gutierrez-Rojas et al., 2008; 
Vojta et al., 2001). Taken together, the above findings suggest 
that persistent depressive symptoms of even subsyndromal 
Fig. 3. Relationship between depressive symptoms and impaired life functioning. 
IDS-C = Inventory of Depressive Symptomatology – Clinician Rated (Altshuler et 
al., 2006). Altshuler et al., Subsyndromal depressive symptoms are associated 
with functional impairment in patients with bipolar disorder: results of a large, 
multisite study. J Clin Psychiatry 67, 1551-1560, 2006. Copyright 2006, Physicians 
Postgraduate Press. Adapted by permission.
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severity should be aggressively targeted to optimize patients’ 
QOL and functioning.
8. Caregiver burden of bipolar depression
Bipolar depression can negatively affect not only BD patients 
but also their caregivers in terms of the temporal, financial, and 
emotional costs of providing care. Semistructured interviews of 
500 primary caregivers for STEP-BD participants revealed that 
depressive (but not manic/hypomanic/mixed) episodes were 
associated with greater caregiver burden, even after controlling 
for longitudinal illness severity (days well in the prior year) 
(Ostacher et al., 2008). In a separate analysis of this sample, 
caregivers with higher, compared with lower, levels of self-
reported burden reported more depression, poorer general health, 
and more chronic medical conditions, and contributed more 
financial resources to the patient during the prior year (Perlick et 
al., 2007). Indeed, generalized psychiatric distress, and increased 
symptoms of depression in particular, are consistent findings 
across studies assessing BD caregiver burden (Steele et al., 2010). 
These results clearly demonstrate that the profound impact of 
bipolar depression reaches beyond affected patients to those who 
care for them.
9. Suicide, suicide attempts, and burden of bipolar depression
In addition to immense burdens for family and significant 
others, attempted and completed suicides are associated with 
large economic costs, such as increased health service utilization 
and work productivity loss (due to attempted suicides) or 
workforce loss (due to completed suicides). Rates of attempted 
and completed suicide are considerably higher among patients 
with BD than in the general population. The estimated annual rates 
of attempted and completed suicide among BD patients are 3.9% 
and 1.4%, respectively, which are approximately one to two orders 
of magnitude greater than the corresponding general population 
rates (0.5% and 0.02%, respectively) (Baldessarini et al., 2006). BD 
patients are more likely than individuals in the general population 
to complete suicide attempts, as demonstrated by the higher ratio 
of completed to attempted suicide in BD (approximately 1:3) 
compared with the general population (1:20 to 1:40) (Baldessarini 
et al., 2006).
The depressive and mixed phases of bipolar illness, compared 
with pure manic states, carry substantially higher risk for suicide. 
Among 415 BD patients in the SFBN, those with a history of 
attempted suicide (compared with those without) had significantly 
greater duration and severity of depressive symptoms over a 
1-year prospective follow-up (Leverich et al., 2006). In another 
study involving prospective follow-up of 176 BDI and BDII patients 
over a mean duration of 1.6 years, a total of 53 suicide attempts 
occurred (involving 20% of patients), all during depressive or 
mixed states (Valtonen et al., 2008). In this study, the incidence 
of suicide attempts was found to be 37-fold higher in mixed 
states and 18-fold higher in major depressive states compared 
with other phases of illness (Valtonen et al., 2008). Similarly, in a 
study involving 290 BDI and BDII patients, followed prospectively 
for a mean of 9.3 years, increased lifetime predominance of 
depressive recurrence and number of mixed episodes per year 
were significant risk factors for both suicidal ideation and suicide 
attempts (Undurraga et al., 2012b). These associations were further 
supported by findings in 928 BDI patients, among whom those 
with depression-predominant illness were significantly more 
likely to have attempted suicide, compared with patients with 
mania as their predominant polarity (Baldessarini et al., 2012). 
Taken together, these findings highlight the critical importance of 
effective treatment of depressive symptoms, whether occurring 
alone or in the context of concurrent mood elevation symptoms 
(i.e., mixed symptoms), to mitigate the increased risk of suicide 
in BD patients.
10. Polypharmacy in bipolar depression
Depressive symptoms in patients with BD are associated 
with prevalent use of antidepressants, which, in turn, may be 
associated with unfavorable (i.e., more challenging and costly) 
illness characteristics, including increases in rapid cycling, mixed 
symptoms, and suicidality (Ghaemi et al., 2003; Goldberg et al., 
2007; Marangell et al., 2008; Undurraga et al., 2012a). Analysis 
of pharmacy claims for 7406 BD patients enrolled in a large 
commercial US health plan revealed that antidepressants were the 
most commonly prescribed class of initial medication regimens, 
despite limited evidence for their efficacy in BD (Baldessarini 
et al., 2008). In this study, one-third of patients were initially 
prescribed two or more psychotropic medications, and this 
proportion remained stable at 1-year follow-up (Baldessarini et 
al., 2008). Such polypharmacy (concurrent use of two or more 
prescription psychotropic medications) is increasingly common 
among BD patients and likely contributes to greater side-effect 
burden and economic costs for patients and society (Baldessarini 
et al., 2008; Frye et al., 2000; Goldberg et al., 2009). At the time 
of entry into the STEP-BD study, 68% of 4035 BD patients were 
prescribed two or more medications, 40% were prescribed three 
or more medications, and 18% took four or more medications (i.e., 
complex polypharmacy) (Goldberg et al., 2009). Patients with at 
least six lifetime depressive episodes and those with a history of 
attempted suicide were at increased risk for receiving complex 
pharmacotherapy (Goldberg et al., 2009). These findings highlight 
the contribution of the depressive phase of bipolar illness to 
the increased burden of polypharmacy among BD patients and 
underscore the challenges faced by clinicians in effectively 
treating patients with bipolar depression.
11. Management of burden associated with bipolar depression
In addition to aggressive pharmacological management of 
depressive symptoms, interventions that address the functional 
impairment and caregiver stress associated with bipolar depression 
are essential for mitigating the substantial burden associated with 
this illness. Functional and cognitive remediation strategies have 
shown promise for reduction of functional impairment in BD. 
In one study involving 239 euthymic BD patients, 21 weeks of 
functional remediation yielded significant improvement in overall 
functioning compared with treatment as usual, with particularly 
strong effects in interpersonal and occupational domains 
(Torrent et al., 2013). In another study, 18 BD patients with 
residual depressive symptoms received 14 sessions of cognitive 
remediation, which resulted in reduced depressive symptoms 
and improved occupational and psychosocial functioning, 
both immediately post-treatment and at 3 months’ follow-up 
(Deckersbach et al., 2010). Psychosocial treatments as adjuncts 
to pharmacotherapy have also demonstrated efficacy in the 
amelioration of functional impairment in BD patients. Evidence-
based approaches – including cognitive behavioral therapy, 
family-focused treatment, and interpersonal and social rhythm 
therapy – may yield improvements not only in long-term mood 
stability but also in social and family functioning and, potentially, 
vocational functioning (Miklowitz, 2011). Thus, interventions that 
target the functional deficits associated with bipolar depression, 
in conjunction with pharmacotherapies targeting depressive 
symptoms, may prove critical in reducing the burden of illness.
Management of caregiver burden is essential for ensuring 
the well-being of family and loved ones of individuals with BD, 
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particularly in light of evidence associating increased caregiver 
burden with poorer clinical outcomes for BD patients (Perlick et 
al., 2004) and the greater overall socioeconomic impact of BD 
(Dilsaver, 2011; Wyatt and Henter, 1995). One study compared 
a variation of family-focused treatment to a video-based health 
education intervention for 46 caregivers of patients with BD, 
finding that family-focused treatment was associated with 
significant reductions in caregiver depression and health risk 
behaviors, as well as decreased depression in patients (Perlick et 
al., 2010). Web-based informational resources (Berk et al., 2013) 
and peer support groups for families of patients with serious 
mental illness (Duckworth and Halpern, 2014) may also be of 
benefit in reducing caregiver burden.
12. Limitations of the study
This review, although comprehensive, provides a study-wise 
aggregate (rather than a patient-wise meta-analytic) summary 
of the relevant literature on this topic. The literature search was 
limited to the PubMed database and to English articles, potentially 
missing relevant non-English articles.
13. Conclusions
BD inflicts substantial burdens upon affected individuals, their 
caregivers, and society in general. Depressive symptoms are more 
pervasive than elevated/mixed symptoms in bipolar illness, and 
consequently account for more illness burden. Specifically, bipolar 
depressive compared with mood elevation symptoms incur 
greater indirect costs due to lost work productivity and increased 
rates of disability. Caregivers of patients with BD also experience 
greater burden due to depressive compared with mood elevation 
symptoms in terms of lost work productivity and general medical 
problems. In addition, syndromal and subsyndromal depression, 
as compared with mood elevation symptoms, yield greater 
impairments of overall functioning and QOL and are associated 
with increased risks of attempted and completed suicide. More 
aggressive and effective treatment of both syndromal and 
subsyndromal depressive symptoms in BD patients, combined 
with adjunctive interventions targeting the functional deficits 
associated with bipolar depression, are essential for alleviating 
the profound burden of this important aspect of this debilitating 
illness. Further studies investigating treatments for bipolar 
depression are warranted, and could benefit by including metrics 
not only for mood outcomes, but also for illness burden.
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